Dorzolamide

Dorzolamide

Clinical data
Trade names	Trusopt
AHFS/Drugs.com	Monograph
MedlinePlus	a602022
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Topical (eye drops)
ATC code	S01EC03 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	~33%
Biological half-life	4 months
Identifiers
IUPAC name (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
CAS Number	130693-82-2 N
PubChem CID	5284549
IUPHAR/BPS	6810
DrugBank	DB00869 Y
ChemSpider	4447604 Y
UNII	9JDX055TW1
KEGG	D07871 N
ChEBI	CHEBI:4702 Y
ChEMBL	CHEMBL218490 Y
Chemical and physical data
Formula	C10H16N2O4S3
Molar mass	324.443 g/mol
3D model (Jmol)	Interactive image
SMILES CCNC1CC(C)S(=O)(=O)c2sc(cc12)S(=O)(=O)N
InChI InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1 Y Key:IAVUPMFITXYVAF-XPUUQOCRSA-N Y
NY (what is this?)

Dorzolamide (trade name Trusopt) is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent, and acts by decreasing the production of aqueous humour. It is administered as a topical ophthalmic in the form of a 2% solution.

This drug, developed by Merck, was the first drug in human therapy (market introduction 1995) which resulted from structure-based drug design. It was developed to circumvent the systemic side effects of acetazolamide which has to be taken orally.

Dorzolamide hydrochloride is used to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension.

It lowers IOP by about 20%.

Ocular stinging, burning, itching and bitter taste. It causes shallowing of the anterior chamber and leads to transient myopia.